SKHY Investors Have Opportunity to Join SK hynix Inc. Fraud Investigation with SBS Law

SKHY Investors Have Opportunity to Join SK hynix Inc. Fraud Investigation with SBS Law

LOS ANGELES–(BUSINESS WIRE)–Schall, Brown & Schwartz LLP (“SBS”), a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of SK hynix Inc. (“SK hynix” or “the Company”) (NASDAQ: SKHY) for violations of the securities laws.

INVESTIGATION DETAILS: The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. SK hynix is the subject of a ruling by a federal judge on November 14, 2026, who declined to dismiss a class action lawsuit against the Company along with Samsung Electronics and Micron that claims it conspired to restrict DRAM supply and inflate prices. Based on this news, shares of SK hynix fell sharply.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall or David Schwartz of Schall, Brown & Schwartz LLP, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm’s website at www.schallfirm.com, or by email at [email protected].

WHY SBS? Schall, Brown & Schwartz LLP represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation. Bringing together the extensive experience and diverse skillsets of founding partners Brian Schall, Andrew Brown, and David Schwartz, SBS is dedicated to aggressively advocating for every investor.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

Schall, Brown & Schwartz LLP
Brian Schall, Esq.,
Andrew Brown, Esq.,
David Schwartz, Esq.,
www.schallfirm.com
Office: 310-301-3335
[email protected]

KEYWORDS: United States North America California

INDUSTRY KEYWORDS: Class Action Lawsuit Professional Services Legal

MEDIA:

Logo
Logo

EMAT Investors Have Opportunity to Join Evolution Metals & Technologies Corp. Fraud Investigation with SBS Law

EMAT Investors Have Opportunity to Join Evolution Metals & Technologies Corp. Fraud Investigation with SBS Law

LOS ANGELES–(BUSINESS WIRE)–Schall, Brown & Schwartz LLP (“SBS”), a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Evolution Metals & Technologies Corp. (“Evolution Metals” or “the Company”) (NASDAQ: EMAT) for violations of the securities laws.

INVESTIGATION DETAILS: The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Evolution Metals is the subject of a report published by Capybara Research on November 16, 2026. The report alleges that the Company’s executives discussed a $2 million payment to silence whistleblower complains over an $82 million loan involving Korea. According to the report, the evidence reveals the Company considered concealing the payment from its auditors. Based on this news, shares of Evolution Metals fell sharply.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall or David Schwartz of Schall, Brown & Schwartz LLP, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm’s website at www.schallfirm.com, or by email at [email protected].

WHY SBS? Schall, Brown & Schwartz LLP represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation. Bringing together the extensive experience and diverse skillsets of founding partners Brian Schall, Andrew Brown, and David Schwartz, SBS is dedicated to aggressively advocating for every investor.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

Schall, Brown & Schwartz LLP

Brian Schall, Esq.,

Andrew Brown, Esq.,

David Schwartz, Esq.,

www.schallfirm.com

Office: 310-301-3335

[email protected]

KEYWORDS: United States North America California

INDUSTRY KEYWORDS: Class Action Lawsuit Professional Services Legal

MEDIA:

Logo
Logo

CVR Energy Announces Pricing of $1.25 Billion of 9.250% Senior Secured Notes Due 2032

CVR Energy Announces Pricing of $1.25 Billion of 9.250% Senior Secured Notes Due 2032

SUGAR LAND, Texas–(BUSINESS WIRE)–
CVR Energy, Inc. (the “Company” or “CVR Energy”) (NYSE: CVI) announced today the pricing of its previously announced private placement (the “Offering”) pursuant to Rule 144A and Regulation S under the Securities Act of 1933, as amended (the “Securities Act”), of $1.25 billion in aggregate principal amount of 9.250% senior secured notes due 2032 (the “Notes”). The Notes will be issued at a price equal to 98.980% of their principal amount. The Notes will mature on March 15, 2032. The Offering is expected to close on November 25, 2026, subject to customary closing conditions. Prior to the closing of the Acquisition (as defined below), the Notes will not be guaranteed and will be secured only by a first-priority security interest in favor of the trustee in the Company’s rights to an escrow account and the funds held therein. Upon the closing of the Acquisition, the Notes are expected to be fully and unconditionally guaranteed on a senior secured basis by each of the Company’s existing and future wholly-owned domestic restricted subsidiaries that guarantee the Company’s new senior secured credit facilities or certain of its other material indebtedness.

In addition, the Company is seeking to enter into a new senior secured term loan B facility in an aggregate principal amount of $1.0 billion and to amend its existing senior secured asset-based revolving credit facility to increase aggregate commitments from $550 million to $1.1 billion. These financing transactions are expected to close substantially concurrently with the Acquisition and are subject to market and other conditions.

Upon the closing of the Acquisition, the Notes and related guarantees are expected to be secured by (i) first-priority liens on substantially all assets of the Company and the guarantors other than excluded assets and assets securing the Company’s asset-based revolving credit facility on a first-priority basis (the “ABL Priority Collateral”) and (ii) second-priority liens on the ABL Priority Collateral, in each case subject to permitted liens and exceptions.

The Company intends to use the net proceeds from the Offering, together with cash on hand and the net proceeds from other related financing transactions, to fund the previously announced acquisition of the St. Paul Park, Minnesota and Mandan, North Dakota refineries and related marketing business from certain subsidiaries of Marathon Petroleum Corporation and MPLX LP (the “Acquisition”), redeem the Company’s outstanding 5.750% Senior Notes due 2028 (the “2028 Notes”) and pay related fees and expenses.

The Offering is not conditioned on the consummation of the Acquisition or the other financing transactions. The net proceeds from the Offering are expected to be deposited into an escrow account pending satisfaction of specified release conditions. If the Acquisition is not consummated on or before October 28, 2027, or the purchase agreement governing the Acquisition is terminated in accordance with its terms, the Company will be required to redeem the Notes at a redemption price equal to 100% of their issue price, plus accrued and unpaid interest to, but excluding, the redemption date.

The offer and sale of the Notes and the related guarantees have not been registered under the Securities Act, or any state securities laws, and unless so registered, these securities may not be offered or sold in the United States except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and applicable state securities laws. The Company plans to offer and sell these securities only to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act and to non-U.S. persons outside the United States pursuant to Regulation S under the Securities Act.

This news release shall not constitute an offer to sell, or the solicitation of an offer to buy, any of these securities or any other securities, nor shall there be any sale of these securities or any other securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful. This news release shall not constitute a notice of redemption under the indenture governing the 2028 Notes.

Forward-Looking Statements

This news release may contain forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended. Statements concerning current estimates, expectations and projections about future prospects, opportunities, plans, actions and events and other statements, concerns, or matters that are not historical facts are “forward-looking statements,” as that term is defined under the federal securities laws. These forward-looking statements include, but are not limited to, statements regarding the expected timing of the closing of the Offering, the intended use of proceeds therefrom, the consummation of the Acquisition and the other financing transactions, the intended redemption of the 2028 Notes, the deposit and release of proceeds from escrow, any special mandatory redemption of the Notes and other aspects of the Offering and the Notes. You can generally identify forward-looking statements by our use of forward-looking terminology such as “outlook,” “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “explore,” “evaluate,” “intend,” “may,” “might,” “plan,” “potential,” “predict,” “seek,” “should,” “upcoming,” “before,” “future,” or “will,” or the negative thereof or other variations thereon or comparable terminology. These forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond our control. Investors are cautioned that various factors may affect these forward-looking statements. These factors and risks include, but are not limited to, market conditions affecting the Offering and the other financing transactions; and the risk that the Acquisition, the Offering or the other financing transactions may not be consummated on the anticipated terms or within the anticipated timeframe, or at all. For additional discussion of risk factors which may affect our results, please see the risk factors and other disclosures included in our most recent Annual Report on Form 10-K, any subsequently filed Quarterly Reports on Form 10-Q and our other Securities and Exchange Commission filings. These and other risks may cause our actual performance or achievements to differ materially from any future performance or achievements expressed or implied by these forward-looking statements. Given these risks and uncertainties, you are cautioned not to place undue reliance on such forward-looking statements. The forward-looking statements included in this news release are made only as of the date hereof. CVR Energy disclaims any intention or obligation to update publicly or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except to the extent required by law.

About CVR Energy, Inc.

Headquartered in Sugar Land, Texas, CVR Energy is a diversified holding company primarily engaged in the petroleum refining and marketing businesses, as well as in the nitrogen fertilizer manufacturing business through its interest in CVR Partners, LP. CVR Energy subsidiaries serve as the general partner and own approximately 37 percent of the common units of CVR Partners, LP.

For further information, please contact:

Investor Relations

Richard Roberts

(281) 207-3205

[email protected]

KEYWORDS: Texas United States North America

INDUSTRY KEYWORDS: Alternative Energy Energy Other Energy Oil/Gas

MEDIA:

Logo
Logo

BlackRock Health Sciences Term Trust (BMEZ) Announces Final Results of Tender Offer

BlackRock Health Sciences Term Trust (BMEZ) Announces Final Results of Tender Offer

NEW YORK–(BUSINESS WIRE)–
BlackRock Health Sciences Term Trust (the “Fund”) announced today the final results of its tender offer (“Tender Offer”) for up to 5% of its outstanding common shares (the “Shares”).

The Tender Offer, which expired at 5:00 p.m. Eastern time on November 18, 2026, was oversubscribed.

Therefore, in accordance with the terms and conditions of the Tender Offer, the Fund will purchase Shares from all tendering shareholders on a pro rata basis, after disregarding fractions, based on the number of Shares properly tendered (“Pro-Ration Factor”). The final results of the Tender Offer are provided in the table below.

Fund Name

Ticker

CUSIP

Number of

Shares

Tendered

Number of

Tendered Shares

to be Purchased

Pro-Ration

Factor

Purchase

Price*

BlackRock Health Sciences Term Trust

BMEZ

09260E105

13,178,845

3,125,070

0.237254

17.8458

*Equal to 98% of the Fund’s net asset value per Share as of the close of regular trading on the New York Stock Exchange on November 19, 2026 (the business day immediately following the expiration date of the Tender Offer).

Payments for Shares tendered and accepted are expected to be made within approximately five business days after the expiration date.

Questions regarding the Tender Offer may be directed to Georgeson LLC, the Information Agent for the Tender Offer, toll free at (866) 961-4074.

IMPORTANT NOTICE

This press release is for informational purposes only and shall not constitute a recommendation, an offer to purchase or a solicitation of an offer to sell any common shares of the Fund. The offer to purchase the Fund’s common shares was made only pursuant to an offer to purchase, a related letter of transmittal and other documents filed with the U.S. Securities and Exchange Commission (“SEC”) as exhibits to a tender offer statement on Schedule TO. Shareholders may obtain a free copy of the offer to purchase and other documents filed with the SEC at the website maintained by the SEC at www.sec.gov or by directing such requests to the Fund.

About BlackRock

BlackRock’s purpose is to help more and more people experience financial well-being. As a fiduciary to investors and a leading provider of financial technology, we help millions of people build savings that serve them throughout their lives by making investing easier and more affordable. For additional information on BlackRock, please visit www.blackrock.com/corporate

Availability of Fund Updates

BlackRock will update performance and certain other data for the Funds on a monthly basis on its website in the “Closed-end Funds” section of www.blackrock.com as well as certain other material information as necessary from time to time. Investors and others are advised to check the website for updated performance information and the release of other material information about the Funds. This reference to BlackRock’s website is intended to allow investors public access to information regarding the Funds and does not, and is not intended to, incorporate BlackRock’s website in this release.

Forward-Looking Statements

This press release, and other statements that BlackRock or a Fund may make, may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act, with respect to a Fund’s or BlackRock’s future financial or business performance, strategies or expectations. Forward-looking statements are typically identified by words or phrases such as “trend,” “potential,” “opportunity,” “pipeline,” “believe,” “comfortable,” “expect,” “anticipate,” “current,” “intention,” “estimate,” “position,” “assume,” “outlook,” “continue,” “remain,” “maintain,” “sustain,” “seek,” “achieve,” and similar expressions, or future or conditional verbs such as “will,” “would,” “should,” “could,” “may” or similar expressions.

BlackRock cautions that forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Forward-looking statements speak only as of the date they are made, and BlackRock assumes no duty to and does not undertake to update forward-looking statements. Actual results could differ materially from those anticipated in forward-looking statements and future results could differ materially from historical performance.

With respect to the Funds, the following factors, among others, could cause actual events to differ materially from forward-looking statements or historical performance: (1) changes and volatility in political, economic or industry conditions, the interest rate environment, foreign exchange rates or financial and capital markets, which could result in changes in demand for the Funds or in a Fund’s net asset value; (2) the relative and absolute investment performance of a Fund and its investments; (3) the impact of increased competition; (4) the unfavorable resolution of any legal proceedings; (5) the extent and timing of any distributions or share repurchases; (6) the impact, extent and timing of technological changes; (7) the impact of legislative and regulatory actions and reforms, and regulatory, supervisory or enforcement actions of government agencies relating to a Fund or BlackRock, as applicable; (8) terrorist activities, international hostilities, health epidemics and/or pandemics and natural disasters, which may adversely affect the general economy, domestic and local financial and capital markets, specific industries or BlackRock; (9) BlackRock’s ability to attract and retain highly talented professionals; (10) the impact of BlackRock electing to provide support to its products from time to time; and (11) the impact of problems at other financial institutions or the failure or negative performance of products at other financial institutions.

Annual and Semi-Annual Reports and other regulatory filings of the Funds with the SEC are accessible on the SEC’s website at www.sec.govand on BlackRock’s website at www.blackrock.com, and may discuss these or other factors that affect the Funds. The information contained on BlackRock’s website is not a part of this press release.

1-800-882-0052

KEYWORDS: New York United States North America

INDUSTRY KEYWORDS: Asset Management Professional Services Finance

MEDIA:

Logo
Logo

Avnet Declares Regular Quarterly Dividend

Avnet Declares Regular Quarterly Dividend

PHOENIX–(BUSINESS WIRE)–Avnet, Inc. (Nasdaq: AVT), a leading global technology distributor and solutions provider, announced that its Board of Directors has approved a regular quarterly cash dividend of $0.37 per share. The dividend will be paid on December 16, 2026, to shareholders of record as of the close of business on December 2, 2026.

About Avnet

As a leading global technology distributor and solutions provider, Avnet has served customers’ evolving needs for more than a century. Through regional and specialized businesses around the world, we support customers and suppliers at every stage of the product lifecycle. We help companies adapt to change and accelerate the design and supply stages of product development. With a unique viewpoint from the center of the technology supply chain, Avnet is a trusted partner that solves complex design and supply chain issues so customers can realize revenue faster. Learn more about Avnet at www.avnet.com. (AVT_IR)

Visit the Avnet Investor Relations website at ir.avnet.com or contact us at [email protected].

Investor Relations Contact
[email protected]

Media Relations Contact
Liam Creighton, 480-643-5027
[email protected]

KEYWORDS: United States North America Arizona

INDUSTRY KEYWORDS: Supply Chain Management Semiconductor Retail Technology Other Technology Hardware

MEDIA:

Logo
Logo

Guardforce AI Announces 1-for-40 Reverse Share Split and Adoption of Dual-Class Share Structure

Class A Ordinary Shares Expected to Begin Trading on a Split-Adjusted Basis on November 24, 2026

NEW YORK, NY , Nov. 19, 2026 (GLOBE NEWSWIRE) — Guardforce AI Co., Limited (“Guardforce AI” or the “Company”) (NASDAQ: GFAI), a technology-enabled service company providing solutions in Agentic AI, smart solutions in automation, robotics, and secured logistics, today announced that, pursuant to the approval of its board of directors and the approval of its shareholders at the Company’s reconvened extraordinary general meeting held on Tuesday, November 3, 2026 at 11:00 a.m. (Hong Kong standard time) (November 2, 2026 at 10:00 p.m. Eastern Time), it is effecting a 1-for-40 share consolidation of its ordinary shares (the “Reverse Share Split”), together with a related capital reduction, share subdivision and re-designation of its share capital into Class A ordinary shares and Class B ordinary shares. The Reverse Share Split and the related capital reduction, share subdivision and re-designation of its share capital are subject to registration by the Registrar of Companies of the Cayman Islands. The Reverse Share Split and re-designation became effective on November 11, 2026, upon registration by the Registrar. The Company’s Class A ordinary shares are expected to begin trading on a split-adjusted basis on the Nasdaq Capital Market at the opening of trading on November 24, 2026. The Class A ordinary shares will replace the existing ordinary shares and continue to trade under the symbol “GFAI” and will have a new CUSIP number G4236L146.


Reverse Share Split Details

Every forty (40) issued and unissued ordinary shares, par value US$0.12 each, will be consolidated into one (1) share, par value US$4.80 each. Immediately afterwards, the par value of each issued share will be reduced to US$0.001 through a capital reduction, and each authorized but unissued share of par value US$4.80 will be subdivided into 4,800 shares of par value US$0.001 each. The Company’s authorized share capital will remain US$36,000,000. The reduction in par value will create a distributable reserve that the Company may use for purposes permitted by law and its articles of association, including to offset accumulated losses.

The Reverse Share Split will reduce the number of issued and outstanding ordinary shares from approximately 31,958,004 to approximately 799,233, subject to adjustment for the rounding up of fractional entitlements described below.


Fractional Shares

No fractional shares will be issued in connection with the Reverse Share Split. Any registered shareholder who would otherwise be entitled to a fractional share will receive one additional whole share, rounded up to the nearest whole number. No cash will be paid in lieu of fractional shares. Shareholders who hold their shares through a broker, bank or other nominee should contact that nominee, as the treatment of fractional entitlements in their accounts is subject to the nominee’s procedures.


Warrants and Other Securities

Proportionate adjustments will be made to the number of shares issuable and the exercise price under the Company’s outstanding warrants, options and other convertible securities in accordance with their terms. Following the Reverse Share Split, each outstanding PIPE warrant will be exercisable for 1/160 of one ordinary share, and the exercise price will be adjusted to US$186 per post-consolidation share.


Re-designation into Class A and Class B Ordinary Shares

Immediately following the Reverse Share Split, the Company’s issued and outstanding shares will be re-designated on a one-for-one basis into approximately 719,199 Class A ordinary shares and approximately 80,034 Class B ordinary shares, each with a par value of US$0.001. The Company’s authorized share capital will be re-designated into 34,500,000,000 Class A ordinary shares, 500,000,000 Class B ordinary shares and 1,000,000,000 preferred shares, each with a par value of US$0.001. The Company’s shareholders also approved the adoption of the Second Amended and Restated Memorandum of Association and the Third Amended and Restated Articles of Association to reflect the new share structure.

Each Class A ordinary share carries one (1) vote and each Class B ordinary share carries twenty (20) votes on all matters submitted to a vote at general meetings of the Company. Class A and Class B ordinary shares vote together as a single class. Holders of Class B ordinary shares may convert them into Class A ordinary shares on a one-for-one basis at any time. Class B ordinary shares convert automatically upon transfer to any person that is not an affiliate of the holder or an existing holder of Class B ordinary shares. Class A ordinary shares are not convertible into Class B ordinary shares.

Immediately following the re-designation, all Class B ordinary shares will be held by Lei Wang, the Company’s Chairwoman and Chief Executive Officer. As a result, Ms. Wang’s voting power will increase from approximately 10% to approximately 69% of the total voting power of the Company’s outstanding shares.


Exchange Agent and Shareholder Actions

VStock Transfer, LLC is acting as exchange agent for the Reverse Share Split. Registered shareholders who hold their shares in book-entry form do not need to take any action; their accounts will be adjusted automatically. Shareholders who hold their shares through a broker, bank or other nominee will have their positions adjusted by that nominee. Holders of physical share certificates will receive instructions for exchanging their certificates from the exchange agent and should not submit certificates until requested to do so.


Equity Incentive Plan Amendment

Shareholders also approved Amendment No. 2 to the Guardforce AI Co., Limited 2022 Equity Incentive Plan, which increases the maximum number of shares available for grant from 15% of the issued and outstanding ordinary shares to 20% of the issued and outstanding Class A ordinary shares at the time of grant.

About Guardforce AI Co., Limited

Guardforce AI Co., Limited (NASDAQ: GFAI) is a technology-enabled service company built on real-world service operations, trusted client relationships, and commercial smart service solutions. With its legacy secured logistics business as the operating foundation, the Company is expanding its first commercial growth curve through Smart Solutions across retail, hospitality, security, and other service environments, while building AI-native services as its second strategic growth engine. For more information, visit www.guardforceai.com, or X (formerly Twitter): @Guardforceai.


Safe Harbor Statement

This press release contains statements that do not relate to historical facts but are
“
forward-looking statements
”
within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements can generally (although not always) be identified by their use of terms and phrases such as
anticipate, appear, believe, continue, could, estimate, expect, indicate, intend, may, plan, possible, predict, project, pursue, will, would and other similar terms and phrases, as well as the use of the future tense. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on current beliefs, expectations and assumptions regarding the future of the business of the Company, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control, including the risks described in our registration statements and Annual Report on Form 20-F filed on April 21, 2026 under the heading
“
Risk Factors
”
as filed with the Securities and Exchange Commission. Actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Forward-looking statements in this press release speak only as of the date hereof. Unless otherwise required by law, we undertake no obligation to publicly update or revise these forward-looking statements, whether because of new information, future events or otherwise.

Guardforce AI Corporate Communications:

Hu Yu
Email: [email protected]



BABA INVESTOR ALERT: Alibaba Group Holding Limited Investors with Substantial Losses May Seek to Lead the Alibaba Class Action Lawsuit – RGRD Law

SAN DIEGO, Nov. 19, 2026 (GLOBE NEWSWIRE) — Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Alibaba Group Holding Limited (NYSE: BABA) publicly traded securities between May 23, 2024 and November 11, 2026, inclusive (the “Class Period”), have until January 19, 2027 to seek appointment as lead plaintiff of the Alibaba class action lawsuit.  Captioned Bihan v. Alibaba Group Holding Limited, No. 26-cv-10158 (S.D.N.Y.), the Alibaba class action lawsuit charges Alibaba and its CEO with violations of the Securities Exchange Act of 1934.

If you suffered substantial losses and wish to serve as lead plaintiff of the Alibaba class action lawsuit, please provide your information here:


https://www.rgrdlaw.com/cases-alibaba-group-holding-class-action-lawsuit-baba.html

You can also contact attorneys

Ken Dolitsky

or

Michael Albert

of Robbins Geller by calling 800/851-7783 or via e-mail at

[email protected]

.

CASE ALLEGATIONS: Alibaba, through its subsidiaries, provides technology infrastructure and marketing reach to help merchants, brands, retailers, and other businesses.

The Alibaba class action lawsuit alleges that throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (i) Alibaba maintained a business relationship with Alice Huang and, through her, Megaspeed, which is suspected of smuggling certain hardware to China illegally; (ii) Alice Huang is suspected of having served as a Chinese spy, and achieved notoriety after her relationship with Jensen Huang, the former CEO of NVIDIA Corporation, was revealed; (iii) the foregoing materially raised the likelihood of reputational damage to Alibaba, as well as the risk that Alibaba would not be able to purchase certain products subject to export control restrictions by the United States; and (iv) as a result, defendants’ public statements about Alibaba’s business, operations, and prospects were materially false and/or misleading at all relevant times.

The Alibaba class action lawsuit further alleges that on November 9, 2026, the Financial Times published an article entitled “Alleged Chinese spy linked to Nvidia chief pitched AI chip deals to investors.”  According to the complaint, the article stated that “Alibaba, via a Singaporean subsidiary called Apex Enterprise Solutions, lent money to Megaspeed,” and further stated facts about Megaspeed’s relationship with Alibaba, facilitated through their respective subsidiaries, Speedmatrix and Apex Enterprise Solutions.  On this news, the price of Alibaba ADSs fell nearly 4% on November 9, 2026, and a further 2.5% the following day, the complaint alleges.

Then, on November 10, 2026, The New York Times, further reporting on the issue of Megaspeed’s significant links to Alibaba, published an article entitled “The Woman in the Middle of Nvidia’s Spy Scandal.”  The complaint alleges the article reported on Alice Huang, including the investigations into her activities, as well as how Alibaba became a “dominant customer” of Megaspeed.  On this news, the price of Alibaba ADSs fell further.

Finally, on November 12, 2026, Reuters published an article entitled “Chinese AI firms rush to secure Nvidia chip capacity as spy scandal stirs fear of US curbs.”  The complaint alleges the article stated that Chinese AI companies were worried the scandal “could spur Washington to tighten restrictions on their remote use of advanced processors.”  On this news, the price of Alibaba ADSs fell 7%.

THE LEAD PLAINTIFF PROCESS: The Private Securities Litigation Reform Act of 1995 permits any investor who purchased or acquired Alibaba publicly traded securities during the Class Period to seek appointment as lead plaintiff in the Alibaba class action lawsuit.  A lead plaintiff is generally the movant with the greatest financial interest in the relief sought by the putative class who is also typical and adequate of the putative class.  A lead plaintiff acts on behalf of all other class members in directing the Alibaba class action lawsuit.  The lead plaintiff can select a law firm of its choice to litigate the Alibaba class action lawsuit.  An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff of the Alibaba class action lawsuit.

ABOUT ROBBINS GELLER: Robbins Geller Rudman & Dowd LLP is one of the world’s leading law firms representing investors in securities fraud and shareholder rights litigation.  Our Firm ranked #1 on the most recent ISS Securities Class Action Services Top 50 Report, recovering more than $916 million for investors in 2025.  This marks our fourth #1 ranking in the past five years.  And in those five years alone, Robbins Geller recovered $8.4 billion for investors – $3.4 billion more than any other law firm.  With 200 lawyers in 10 offices, Robbins Geller is one of the largest plaintiffs’ firms in the world, and the Firm’s attorneys have obtained many of the largest securities class action recoveries in history, including the largest ever – $7.2 billion – in In re Enron Corp. Sec. Litig.  Please visit the following page for more information:


https://www.rgrdlaw.com/services-litigation-securities-fraud.html

Past results do not guarantee future outcomes. 
Services may be performed by attorneys in any of our offices. 

Contact:
            Robbins Geller Rudman & Dowd LLP
            Ken Dolitsky
            Michael Albert
            655 W. Broadway, Suite 1900, San Diego, CA 92101
            800/851-7783
            [email protected]



Mesoblast Wins Deloitte Tech Fast 50 Leadership & Enterprise Growth Award

NEW YORK, Nov. 19, 2026 (GLOBE NEWSWIRE) — Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced it has received the Leadership & Enterprise Growth Award at the Deloitte Technology Fast 50 Australia Awards which recognizes Australia’s fastest-growing technology companies and the founders, innovators and leaders shaping the future of the sector.

The award recognizes Mesoblast’s successful evolution to a commercial-stage biotechnology company following its U.S. launch of Ryoncil® (remestemcel-L-rknd), the first mesenchymal stromal cell therapy approved by the U.S. Food and Drug Administration (FDA).1

“We are pleased to receive this award from Deloitte which recognizes Mesoblast’s leadership excellence across innovation and scalability in the healthcare industry,” said Mesoblast Chief Executive Dr. Silviu Itescu. “The successful launch of RYONCIL has established a strong commercial foundation for Mesoblast and has enabled patients to access a life changing product. We are focused on building on that foundation, progressing our broader portfolio and delivering sustainable growth and long-term value for our shareholders.”

About Mesoblast

Mesoblast (the Company) is a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The therapies from the Company’s proprietary mesenchymal lineage cell therapy technology platform respond to severe inflammation by releasing anti-inflammatory factors that counter and modulate multiple effector arms of the immune system, resulting in significant reduction of the damaging inflammatory process.

Mesoblast’s Ryoncil® (remestemcel-L-rknd) for the treatment of steroid-refractory acute graft versus host disease (SR-aGvHD) in pediatric patients 2 months and older is the first FDA-approved mesenchymal stromal cell (MSC) therapy. Please see the full Prescribing Information at www.ryoncil.com.

Mesoblast is committed to developing additional cell therapies for distinct indications based on its remestemcel-L and rexlemestrocel-L allogeneic stromal cell technology platforms. Ryoncil® is being developed for additional inflammatory diseases including SR-aGvHD in adults and biologic-resistant inflammatory bowel disease. Rexlemestrocel-L is being developed for heart failure and chronic low back pain. The Company has established commercial partnerships in Japan, Europe and China.

About Mesoblast intellectual property: Mesoblast has a strong and extensive global intellectual property portfolio, with over 1,000 granted patents or patent applications covering mesenchymal stromal cell compositions of matter, methods of manufacturing and indications. These granted patents and patent applications provide commercial protection extending through to at least 2044 in all major markets.

About Mesoblast manufacturing: The Company’s proprietary manufacturing processes yield industrial-scale, cryopreserved, off-the-shelf, cellular medicines. These cell therapies, with defined pharmaceutical release criteria, are planned to be readily available to patients worldwide.

Mesoblast has locations in Australia, the United States and Singapore and is listed on the Australian Securities Exchange (MSB) and on the Nasdaq (MESO). For more information, please see www.mesoblast.com, LinkedIn: Mesoblast Limited and X: @Mesoblast

References / Footnotes

  1. Please see the full Prescribing Information at www.ryoncil.com

Forward-Looking Statements

This press release includes forward-looking statements that relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. We make such forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Forward-looking statements should not be read as a guarantee of future performance or results, and actual results may differ from the results anticipated in these forward-looking statements, and the differences may be material and adverse. Forward-looking statements include, but are not limited to, statements about: the initiation, timing, progress and results of Mesoblast’s preclinical and clinical studies, and Mesoblast’s research and development programs; Mesoblast’s ability to advance product candidates into, enroll and successfully complete, clinical studies, including multi-national clinical trials; Mesoblast’s ability to advance its manufacturing capabilities; the timing or likelihood of regulatory filings and approvals, manufacturing activities and product marketing activities, if any; the commercialization of Mesoblast’s RYONCIL for pediatric SR-aGVHD and any other product candidates, if approved; regulatory or public perceptions and market acceptance surrounding the use of stem-cell based therapies; the potential for Mesoblast’s product candidates, if any are approved, to be withdrawn from the market due to patient adverse events or deaths; the potential benefits of strategic collaboration agreements and Mesoblast’s ability to enter into and maintain established strategic collaborations; Mesoblast’s ability to establish and maintain intellectual property on its product candidates and Mesoblast’s ability to successfully defend these in cases of alleged infringement; the scope of protection Mesoblast is able to establish and maintain for intellectual property rights covering its product candidates and technology; estimates of Mesoblast’s expenses, future revenues, capital requirements and its needs for additional financing; Mesoblast’s financial performance; developments relating to Mesoblast’s competitors and industry; and the pricing and reimbursement of Mesoblast’s product candidates, if approved. You should read this press release together with our risk factors, in our most recently filed reports with the SEC or on our website. Uncertainties and risks that may cause Mesoblast’s actual results, performance or achievements to be materially different from those which may be expressed or implied by such statements, and accordingly, you should not place undue reliance on these forward-looking statements. We do not undertake any obligations to publicly update or revise any forward-looking statements, whether as a result of new information, future developments or otherwise.

Release authorized by the Chief Executive.

For more information, please contact:


Corporate Communications / Investors
 
Paul Hughes  
T: +61 3 9639 6036  
   

Media – Global

Media – Australia
Rubenstein BlueDot Media
Caroline Nelson Steve Dabkowski
T: +1 703 489 3037 T: +61 419 880 486
E:[email protected] E:[email protected]



CareScout Focuses Strategic Direction on Aging Care Services

CareScout Focuses Strategic Direction on Aging Care Services

RICHMOND, Va.–(BUSINESS WIRE)–CareScout today announced a singular focus on its aging care services business and plans to discontinue new insurance sales through CareScout Insurance Company in accordance with applicable regulatory requirements.

The decision reflects CareScout’s belief that its services business offers the greatest opportunity to help millions of families navigate aging care for their loved ones and create long-term value for Genworth shareholders.

“We set out to make the aging journey more confident, connected, and clear, and that ambition has not changed,” said Samir Shah, CEO of CareScout. “We are choosing to focus our investment on a capital-light services business where we see the greatest opportunity for growth and long-term value creation. Together with our partners, we can help more families plan for and manage the care of aging loved ones as their needs evolve.”

CareScout brings together cost-of-care insights, care expertise, personalized guidance, and access to quality care to help families understand their needs, explore their options, and take the next steps with confidence. Building on these capabilities, the company will work with insurers, employers, advisors, and care providers to reach more families and broaden its services across the aging journey.

Existing CareScout Insurance policies remain in force with no change to servicing contacts or processes, and CareScout Insurance Company remains committed to meeting all contractual obligations. The decision is not expected to have a material impact on Genworth’s financial condition or results of operations.

About CareScout

CareScout helps older adults and their families navigate the aging journey, find, and fund quality care. Inspired by a mission to simplify and dignify the aging experience, we’re building an integrated ecosystem of care and funding solutions. To learn more about CareScout, visit www.CareScout.com. CareScout is a wholly owned subsidiary of Genworth Financial, Inc. (NYSE: GNW). CareScout is the marketing name for CareScout Holdings, Inc., its affiliates and entities. Affiliates and entities are solely and separately responsible for their own financial and contractual obligations.

Cautionary Note Regarding Forward-Looking Statements

This press release contains certain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates,” “will,” or words of similar meaning and include, but are not limited to, statements regarding CareScout Insurance Company’s (Company) decision to discontinue new insurance sales. Examples of forward-looking statements include statements CareScout makes relating to the timing and potential costs associated with the discontinuation, the anticipated effects on CareScout’s operations, the potential impact on the financial performance of the Company and Genworth Financial, Inc. (Genworth), and the Company’s plans with respect to customers and other stakeholders affected by the discontinuation. Forward-looking statements are based on management’s current expectations and assumptions, which are subject to inherent uncertainties, risks, and changes in circumstances that are difficult to predict. Actual outcomes and results may differ materially due to global political, economic, business, competitive, market, regulatory, and other factors and risks, as well as risks discussed in the risk factor section of Genworth’s Annual Report on Form 10-K, filed with the United States Securities and Exchange Commission on February 27, 2026. Genworth undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise.

Investors

Christine Jewell, [email protected]

Media:

Evans Mandes, [email protected]

KEYWORDS: Virginia United States North America

INDUSTRY KEYWORDS: Insurance Finance Seniors Professional Services Health Insurance Family Managed Care Health Consumer

MEDIA:

Logo
Logo

Molson Coors Beverage Company Announces Regular Quarterly Dividend

Molson Coors Beverage Company Announces Regular Quarterly Dividend

GOLDEN, Colo. & MONTREAL–(BUSINESS WIRE)–
The Board of Directors of Molson Coors Beverage Company (NYSE: TAP, TAP.A) today declared a regular quarterly dividend on its Class A and Class B common stock of US$0.48 per share, payable December 18, 2026, to stockholders of record on December 4, 2026. The quarterly dividend is payable to holders of Class A and Class B common stock of Molson Coors Beverage Company.

In addition, the Board of Directors of Molson Coors Canada Inc. (TSX: TPX.B, TPX.A) today declared a quarterly dividend of approximately CAD$0.68 (the Canadian dollar equivalent of the dividend declared on Molson Coors Beverage Company stock), payable December 18, 2026, to its Class A and Class B exchangeable shareholders of record on December 4, 2026. The dividends declared in respect of the Class A and Class B exchangeable shares are eligible dividends for Canadian tax purposes.

OVERVIEW OF MOLSON COORS BEVERAGE COMPANY

For more than two centuries, we have brewed beverages that unite people to celebrate all life’s moments. From our core power brands, Coors Light, Miller Lite, Coors Banquet, Molson Canadian, Carling and Ožujsko to our above premium brands, including Madrí Excepcional, Staropramen, Blue Moon Belgian White and Leinenkugel’s Summer Shandy, to our value brands, like Miller High Life and Keystone Light, we produce many beloved and iconic beers. While our history is rooted in beer, we offer a modern portfolio that expands beyond the beer aisle as well, including flavored beverages like Vizzy Hard Seltzer and Monaco, spirits and non-alcoholic beverages. We also have partner brands, such as Simply Spiked, ZOA Energy, Fever-Tree, among others, through license, distribution, partnership and joint venture agreements. As a business, our ambition is to be the first choice for our people, our consumers and our customers, and our success depends on our ability to make our products available to meet a wide range of consumer segments and occasions.

To learn more about Molson Coors Beverage Company, visit molsoncoors.com.

ABOUT MOLSON COORS CANADA INC.

Molson Coors Canada Inc. (“MCCI”) is a subsidiary of Molson Coors Beverage Company. MCCI Class A and Class B exchangeable shares offer substantially the same economic and voting rights as the respective classes of common shares of MCBC, as described in MCBC’s annual proxy statement and Form 10-K filings with the U.S. Securities and Exchange Commission. The trustee holder of the special Class A voting stock and the special Class B voting stock has the right to cast a number of votes equal to the number of then outstanding Class A exchangeable shares and Class B exchangeable shares, respectively.

Investor Relations

[email protected]

News Media

[email protected]

KEYWORDS: United States North America Canada Colorado

INDUSTRY KEYWORDS: Retail Food/Beverage Wine & Spirits

MEDIA:

Logo
Logo